Marshall Wace
AZN icon

Marshall Wace’s AstraZeneca AZN Stock Holding History

Marshall Wace’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$7.67K – 2952
2025
Q3 		$7.67K Buy
+50
New +$7.57K ﹤0.01% 2815

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Marshall Wace's AZN Position: Q2 2026 in Review

Marshall Wace increased its AstraZeneca (AZN) stake by 71% in Q2 2026, buying an estimated $65.6M and bringing the position to 841,164 shares worth $160M. The position accounts for 0.13% of the portfolio, ranked #119.

Marshall Wace first reported a position in AZN in Q1 2014 and has held it in 37 quarters since. The position peaked at $254M in Q4 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Marshall Wace held 841,164 shares of AstraZeneca worth $160M as of Q2 2026.
  • Marshall Wace bought 348,718 AstraZeneca shares in Q2 2026, an estimated $65.6M.
  • AstraZeneca made up 0.13% of Marshall Wace's portfolio in Q2 2026, its #119 holding.
  • Marshall Wace first reported a position in AstraZeneca in Q1 2014 and has held it in 37 quarters since.
  • Marshall Wace's AstraZeneca position peaked at $254M in Q4 2024.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.